Identification of Risk Phenotypes for Sarcopenia Using DXA WBC, Anthropometric and MA Among Young Adults

Identification of Risk Phenotypes for Sarcopenia Using DXA Whole Body Composition, Anthropometric and Muskuloskeltal Analysis Among Young Adults

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06739850

Enrollment

221

Registered

2024-12-18

Start date

2024-02-28

Completion date

2025-03-01

Last updated

2024-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Brief summary

This cross-sectional study aims to identify risk phenotypes for sarcopenia among young adults using Dual-energy X-ray Absorptiometry (DXA) for whole-body composition analysis, along with anthropometric and musculoskeletal assessments. Sarcopenia, characterized by the loss of muscle mass and strength, is a growing concern, particularly among the aging population.

Detailed description

However, early identification in young adults can allow for preventive strategies to improve long-term health outcomes. This study, involving 221 participants aged 15 to 35, focuses on assessing the correlation between DXA-derived body composition, musculoskeletal fitness, and anthropometric measurements with sarcopenia risk. Primary outcome measures include DXA imaging and dynamometry for body composition and strength evaluation, while secondary outcomes focus on detailed anthropometric and musculoskeletal analyses. By addressing early risk factors in younger populations, this research hopes to enhance understanding of sarcopenia's development and support early intervention strategies. Data collection is conducted at the Center of Nuclear Medicine in Lahore, Pakistan.

Interventions

COMBINATION_PRODUCTIdentification of Risk Phenotypes of Sarcopenia

Sarcopenia is a condition characterized by progressive loss of skeletal muscle mass, strength, and function, often associated with aging. Traditionally, it is studied in older populations, but your focus is on identifying its early manifestations in young adults, potentially offering a window for prevention.

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

15 Years to 35 Years

Healthy volunteers

Inclusion criteria

* Young Adults ( between 15-35) (7)

Exclusion criteria

* Elderly Patients * Children below the age of 18 Years * Diagnosed Malignancy * Diagnosed Patients * Diseased Individuals such as Chronic Illness and Malignancies

Design outcomes

Primary

Measure	Time frame	Description
DXA	12 Months	DXA Whole Body Imaging is a primary tool of measure for my study

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026